厄贝沙坦联合氨氯地平对糖尿病合并高血压疗效观察

Clinical Effect and Investigation of Irbesartan and Amlodipine Adm in istration in Diabetic Patients with Hypertension

目的:观察厄贝沙坦联合氯氨地平对糖尿病合并高血压病的降压效果及对肾脏的保护作用。方法:糖尿病合并高血压病患者90例随机分为三组,每组各30例,厄贝沙坦组(予厄贝沙坦150～300mg/日),氨氯地平组(予氨氯地平5～10mg/日),联合治疗组(予厄贝沙坦150mg+氨氯地平5mg/日),均治疗12周,三组分别测定治疗前后静息状态下血压,采用放免法测定尿白蛋白排泄率(UAER)。结果:治疗8周后各组收缩压、舒张压均较治疗前明显下降,差异有统计学意义(P<0.05);而联合治疗组降压疗效优于厄贝沙坦组和氨氯地平组,差异有统计学意义(P<0.05)。治疗后联合治疗组和厄贝沙坦组UAER均较治疗前明显下降,差异有统计学意义(P<0.05),联合治疗组与氨氯地平组比较,UAER呈进一步下降趋势,差异有明显统计学意义(P<0.01)。结论:厄贝沙坦联合氨氯地平治疗糖尿病合并高血压病效果优于单一用药,能使血压达到理想控制标准值,减轻靶器官损害,且无明显不良反应。

Objective：To investigate effects and protective effects on kindney of Irbesartan and amolodipine in diabetic patientswith hypertension. Methods：90 diabetic patientswith hypertension hospitalized were divided into three groups randomly （n = 30 in each group）. Irbesartan group was given oral Irbesartan 150 mg per day, amolodipine group given amolodip ine 5 mg per day, combination group given Irbesartan 150 mg and amolodip ine 5 mg per day. All the patients received 12week treatment. Blood p ressure and urine albumin excretion rate （urinary albumin excretion rate, UAER） were measured by radioimmunoassay in all patients before and after treatment. Results： Systolic and diastolic blood p ressureed after treatment in the three groups significantly improved with statistical significance（P〈0.05）, but systolic and diastolic blood pressures in combination group showed better improvement than that of Irbesartan group and amolodipine group after treatment（P〈0.05）. UAER in combination group and Irbesartan group obviously improved after the treatment（P〈0.05）, and UAER in combination group was lower than that of amolodipine group（P〈0.01）. Conclusions：Irbesartan with amolodipine administration should effected for diabetic patientswith hypertension and it can control blood pressure in an idealway and reduce damage to target organswith no obvious side effect.